Cardiac Therapies Emerge as India’s Best-Selling Drug Segment

Market research data shows that cardiac medications recorded the highest sales in India in 2025, driven by rising non-communicable diseases such as hypertension, lipid disorders, and heart failure. The cardiac segment reached a valuation of over ₹33,000 crore and is expected to continue strong growth alongside respiratory and anti-diabetes medicines.

Source: Economic Times (The Economic Times)

`Sun Pharma Advanced Research to Reduce Workforce by 40%`

Sun Pharma Advanced Research Company (SPARC) announced a major workforce reduction of about 40%, including more than 80% of its U.S. staff, as part of a strategic cost optimisation effort to improve operational focus and strengthen long-term growth prospects in key markets.

Source: Reuters via Economic Times (The Economic Times)

`Torrent Group Plans 500-Bed Multispecialty Hospital in Ahmedabad`

The Torrent Group is entering full-scale hospital care with plans to build a 500-plus bed multispecialty hospital on the SP Ring Road in Ahmedabad. The project — backed by an investment of over ₹750 crore — will create around 2,400 jobsand deepen the company’s footprint across diagnostics, clinical care, and related healthcare services.

Source: Times of India (The Times of India)

`Semaglutide Patent Expiry Could Open ~₹50 Billion Opportunity for Indian Generics`

With key semaglutide patents expiring soon, the Indian generic drug market is poised to tap a potential ₹50 billion revenue opportunityover the next 12–15 months. Analysts expect Indian manufacturers to launch affordable versions in domestic and select regulated markets, boosting competition and access to diabetes and weight-management therapies.

Source: Times of India (The Times of India)

`NPPA Fixes Retail Prices of 37 Key Formulations`

India’s National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices for 37 drug formulations, including widely used cardiovascular and metabolic medicines like atorvastatin, telmisartan, bilastine, and montelukast. The move aims to balance affordability with industry sustainability.

Source: Medical Dialogues (Medical Dialogues)

📌 Daily Pulse Insight

Today’s headlines show a dynamic mix of industry restructuring, capacity expansion, regulatory action, and market growth trends:

✔ Strategic restructuring continues, with research arm workforce optimisation at a major pharma player. ✔ Healthcare infrastructure expansion signals rising demand for hospital care services. ✔ Patent expiries are creating massive generics opportunities. ✔ Chronic disease medications are sustaining robust demand. ✔ Price regulation remains a key policy tool to balance access with industry viability.

These developments reflect how the Indian healthcare and pharma ecosystem is rapidly adapting to disease burdens, regulatory shifts, and growth opportunities in 2026.

✨ Follow Daily Pulse for concise, credible healthcare & pharma insights delivered daily. #DailyPulse #HealthcareNews #PharmaUpdates #HealthcareInfrastructure #GenericDrugs #RegulatoryNews #IndiaHealthcare

Disclaimer: The views and opinions expressed in this interview are those of the author and do not reflect the official position of any medical body or organization. 
The author is not a medical doctor; however, the insights shared are based on over a decade of working experience in the healthcare sector start-ups. 
Readers should consult with a qualified healthcare professional for medical advice or information related to their specific situation.

Please follow our page Aristocrat Media for more updates 
For Enquiries connect us on:
marketing@aristocrat-media.com